SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as discussions around metaverse spending cuts fuel optimism and a potential shift in focus. Community members are pointing to positive technical indicators and discussing potential price movements, with some highlighting the impact of AI initiatives. Overall sentiment seems bullish, with many anticipating further gains.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as investors anticipate upcoming earnings, with discussions centering on the company's potential to capitalize on the AI automation trend. The community is weighing the possibility of a breakout, pointing to strong fundamentals and partnerships, while also acknowledging the stock's historical volatility and the need for positive guidance. Some are hoping for a meme-stock rally, while others focus on long-term growth.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

Polyrizon ($PLRZ) is trending due to promising results for its intranasal naloxone hydrogel, sparking significant after-hours momentum. The community is actively discussing the potential for a short squeeze reminiscent of other Israeli momentum stocks, while some traders are wary of potential dilution. With a low float, the stock is exhibiting high volatility, leading to speculation about potential price targets and comparisons to past high-flying stocks.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending following its earnings report, with initial positive reactions tempered by concerns about future performance and AI disruption; the community is actively debating whether the company's growth justifies its valuation and if its AI strategy is strong enough. Some investors express skepticism, citing a lack of trust in leadership and concerns about the company's ability to adapt to the evolving tech landscape, while others remain optimistic about its long-term potential.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending due to a mix of reactions to its latest earnings report and a new partnership with Palantir, with community discussions focusing on forward guidance and AI integration. Despite some initial concerns about revenue growth, several brokerages have raised their price targets, citing the company's growing AI ecosystem. The partnership with Palantir is also a key talking point, with investors speculating on the potential enterprise opportunities it could unlock.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending amid speculation about a potential Fed rate cut in December, fueled by dovish comments from Fed officials and recent economic data. Community members are debating whether this rally is sustainable or if it's a bull trap before a deeper correction, with some pointing to oversold conditions in tech and potential rotation into value stocks. Discussions also involve the impact of economic data, upcoming announcements, and technical analysis on the ETF's price movement.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth ($USAR) is trending due to a newly announced supply agreement between its subsidiary, Less Common Metals, and Solvay and Arnold Magnetic Technologies to supply rare earth metals. The community is discussing the significance of this agreement for rare earth independence and potential government support, while also debating the stock's volatility and comparing it to competitors.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as the community discusses its potential in AI following leadership changes and analysts predict record iPhone shipments. The stock's recent all-time high has sparked debate about its valuation, with some seeing a breakout while others anticipate a pullback. Discussions also revolve around potential partnerships and the impact of broader economic factors.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai ($AI) is trending amid discussions around government contracts and a potential shift away from competitors. The community is weighing the company's growth prospects against concerns about revenue and profitability, while some anticipate a short squeeze. Speculation about a possible acquisition is also circulating.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation about its potential bid for Warner Bros. Discovery's studio and streaming assets, with community discussions focusing on whether this acquisition would be beneficial or lead to overspending. Some investors are optimistic about Netflix's growth potential regardless of the outcome, while others express concerns about the company's strategic direction and content choices, alongside observations around technical indicators and options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Redemplo was approved by the FDA earlier this month, marking a milestone for Arrowhead as it becomes a commercial-stage company.</li><li>The company said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis.</li><li>Arrowhead reported revenue of $829.4 million in fiscal year 2025, compared to $3.55 million in FY24.</li></ul> Morgan Stanley on Wednesday raised its price target on Arrowhead Pharmaceuticals (ARWR) to $48 from $45 while keeping an ‘Equal Weight’ rating on the shares.Shares of the company traded 22% higher at the time of writing on Wednesday morning.According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)." Severe hypertriglyceridemia refers to a medical condition where there are dangerously high levels of triglycerides in the blood.<h2 class="st-heading-2">Significance Of Redemplo Approval</h2>Redemplo is Arrowhead’s first FDA-approved medicine. Its approval earlier this month as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome marked a milestone for Arrowhead as it evolves into a commercial-stage pharmaceutical company.Familial chylomicronemia syndrome (FCS) is a rare, genetic disorder where the body cannot properly break down fat, leading to extremely high levels of triglycerides in the blood. Arrowhead estimates that about 6,500 people in the U.S. are living with FCS.“Arrowhead is truly just getting started, and we are well-positioned to execute on our aggressive goals in discovery, clinical development, business development, and commercial to enable multiple potential new launches, both independently and with partners, over the coming years,” Arrowhead CEO Christopher Anzalone said on Tuesday.The company also said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis due to high triglyceride levels.<h2 class="st-heading-2">FY25 Earnings</h2>Arrowhead <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-reports-2025-fiscal-year-end-results/">reported</a> revenue of $829.4 million in fiscal 2025 (FY25), compared to $3.6 million in FY24, and above an analyst estimate of $757.44 million.Net loss per share came in at $0.01, down from the loss of $5 reported in FY24, and lower than an analyst estimate of a loss of $0.03 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ARWR jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume remained at 'high' levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than tripled this year and risen by about 172% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-posts-unexpected-loss-in-q3-as-ev-sales-drop/cL53uOfREWq">Li Auto Posts Unexpected Loss In Q3 As EV Sales Drop</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target

According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)."

Equity

<ul class="summary-bullets"><li>The company said its net loss for the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024.</li><li>The company is now seeking a re-examination of CHMP’s opinion on its Alzheimer’s drug, Blarcamesine.&nbsp;</li><li>It expects a cash runway of more than 3 years.</li></ul> Shares of Anavex Life Sciences Corp. (AVXL) jumped 10% on Monday afternoon after the company reported a lower-than-expected loss for the fourth quarter.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-upd">said</a> that net loss in the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024, and lower than the loss of $0.15 per share expected by analysts, according to data from Fiscal AI.The company ended the quarter with cash and cash equivalents of $102.6 million. It now expects a cash runway of more than 3 years.<h2 class="st-heading-2">Blarcamesine’s Path Forward</h2>Anavex is focused on developing treatments for neurodegenerative disorders like Alzheimer’s. “There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer’s disease,” said CEO Christopher U. Missling.Earlier this month, Anavex<a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E"> said</a> that a European Medicines Agency (EMA) committee did not recommend approval of the company’s application for its Alzheimer’s drug, Blarcamesine. The Committee for Medicinal Products for Human Use provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens the chances of EMA approval for the drug.The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion. The firm reiterated the course of action on Tuesday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that they are “cautiously optimistic” about the stock’s future.<stembedurl>https://stocktwits.com/Filldagap/message/637414773</stembedurl>AVXL stock is down 68% this year and by 63% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pmcb-stock-jumps-after-company-sells-stake-in-femasys/cL52o2lREgL">PMCB Stock Jumps 25% After Company Sells Stake In Femasys</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug

Anavex ended the quarter with cash and cash equivalents of $102.6 million.

<ul class="summary-bullets"><li>Stifel’s new price target implies a potential upside of about 22% from the stock’s closing price on Friday.&nbsp;</li><li>The analyst noted that the company's headwinds are easing following CMS's large positive reimbursement revision on Friday.&nbsp;</li><li>Meanwhile, Nephron Research also upgraded INSP to ‘Buy’ from ‘Hold’ on Monday.</li></ul> Stifel analyst Jonathan Block on Monday upgraded Inspire Medical Systems (INSP) to ‘Buy’ from ‘Hold’ while also hiking the price target in light of the Centers for Medicare &amp; Medicaid Services’ (CMS) changes to 2026 medical procedure reimbursement rates. &nbsp;The analyst raised the stock's price target to $110, up from $100. The new price target implies about a 22% upside from the stock’s closing price on Friday.Shares of the company traded 29% higher at the time of writing.<h2 class="st-heading-2">Analyst Take</h2>According to the analyst, the company's headwinds are easing following CMS's large positive reimbursement revision on Friday.Stifel sees Inspire's headwinds turning into tailwinds, including patient warehousing, which it believes will now likely aid 2026 volumes. In addition, Inspire's advertising spend, which was curtailed notably in 2024 and early 2025, has picked up lately, the firm added, as per TheFly.Inspire Medical makes the Inspire V implant to treat obstructive sleep apnea. It is installed in an approximate 60-minute outpatient procedure for which the CMS boosted reimbursement rates on Friday at both hospitals and ambulatory surgical centers. &nbsp;Meanwhile, Nephron Research also upgraded INSP to ‘Buy’ from ‘Hold’ on Monday following the news.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around INSP jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/INSP">INSP stock</a> fell 37% this year and by about 42% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-goes-short-on-capircor-therapeutics/cL5bQHUREQS">‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Why Did INSP Stock Soar 29% Today?

Stifel hiked its price target on Inspire Medical Systems to $110, up from $100, following the Centers for Medicare & Medicaid Services’ (CMS) changes to 2026 medical procedure reimbursement rates.

<ul class="summary-bullets"><li>Bath &amp; Body Works now expects annual adjusted earnings per diluted share to be at least $2.87, compared to the prior estimate of $3.35 to $3.60.</li><li>The company added that the fourth-quarter outlook includes the anticipated impact of all tariff rates currently in effect, levied by the U.S. government and other countries.</li><li>The company reported third-quarter net sales of $1.59 billion, compared with Wall Street expectations of $1.63 billion, according to data from Fiscal AI.</li></ul>Bath &amp; Body Works (BBWI) shares tumbled nearly 23% in early trading on Thursday after CEO Daniel Heaf noted that the company’s third-quarter results were below expectations and that the retailer was lowering its outlook for the remainder of the year to reflect current business trends and the continuation of recent macro consumer pressures.&nbsp;“While this is disappointing, we are acting swiftly and decisively to position the business for sustainable, long-term growth,” Heaf said. He added that the consumers will begin to see the benefits of these changes in the coming quarters, though it will take time for the impact to be reflected in the company’s financial performance.The company said it was revising its full-year 2025 net sales guidance to a decline in the low single digits, compared with the previous forecast of 1.5% to 2.7% growth. Bath &amp; Body Works now expects annual adjusted earnings per diluted share to be at least $2.87, compared to the prior estimate of $3.35 to $3.60.<h2 class="st-heading-2">BBWI’s Transformation Plan</h2>Heaf outlined a plan to turn the struggling personal care products company around at a time when demand for its scented candles and perfumes had taken a hit from consumers, mainly in the United States, shunning purchases of higher-end products due to price hikes in the economy.The CEO noted that the plan focuses on Bath &amp; Body Works’ investments mainly by creating “disruptive and innovative” products, reigniting the brand, winning in the marketplace, and operating with speed and efficiency.“We will transform Bath &amp; Body Works to be a faster and more efficient organization. Work has already begun, and we will continue to break down silos, speed up decision making and strengthen the agile operating model that makes this company great,” the company said.Bath &amp; Body Works said that, as part of its turnaround plans, it expects to deliver $250 million in cost savings over two years, with over half of those identified for 2026. “These savings will be used to invest in revenue-generating initiatives across product and brand,” the company said.<h2 class="st-heading-2">Holiday Quarter Forecast</h2>The company said it expects fourth-quarter 2025 net sales to be down in the high single digits, compared with $2.79 billion in the fourth quarter of 2024. Bath &amp; Body Works said that fourth-quarter earnings per share are expected to be at least $1.70, compared to $2.09 a year ago.“Our fourth quarter guidance reflects the continuation of recent negative macro consumer sentiment weighing heavily on our consumers’ purchase intent,” the company said.Bath &amp; Body Works added that the fourth-quarter outlook includes the anticipated impact of all tariffs currently in effect, levied by the U.S. government and other countries.The company reported third-quarter net sales of $1.59 billion, compared with Wall Street expectations of $1.63 billion, according to data from Fiscal AI. Its quarterly adjusted earnings per share were $0.35, compared with estimates of $0.40.<h2 class="st-heading-2">What Is Retail Thinking?</h2>Retail sentiment on Bath &amp; Body Works jumped to ‘extremely bullish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/BBWI">Shares of Bath &amp; Body Works</a> have declined over 45% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/walmart-raises-fy26-outlook-outgoing-ceo-mc-millon-says-retailer-is-winning-market-share/cLPAL6oRE9x">Walmart Raises FY26 Outlook, Outgoing CEO McMillon Says Retailer Is Winning Market Share</a>

The Bath & Body Works logo is displayed at one of their bookstores on March 14, 2025 in Las Vegas, Nevada.

BBWI Stock Cracks After CEO Warns Of Tough Holiday Quarter, Slashes Full-Year Guidance

The company said it was revising its full-year 2025 net sales guidance to a decline in the low single digits, compared with the previous forecast of 1.5% to 2.7% growth.

<ul class="summary-bullets"><li>Joby noted that the sandbox will serve as a base for evaluating potential air taxi operations in the region.</li><li>Saudi Arabia joins the U.S., the U.K., Japan, South Korea and the UAE as another key launch market for Joby's air taxi service.</li><li>In September, the company announced a long-term collaboration with the Ras Al Khaimah Transport Authority and Skyports Infrastructure to launch a passenger air taxi service network in the Emirate of Ras Al Khaimah by 2027.</li></ul>Joby Aviation (JOBY) said on Wednesday it has signed a memorandum of understanding with Red Sea Global and The Helicopter Company that includes plans for Joby to complete pre-commercial evaluation flights of its electric air taxi in Saudi Arabia in the first half of 2026.The company said that under the agreement, Joby will work together with Red Sea Global, the developer behind regenerative tourism destinations The Red Sea and AMAALA, and The Helicopter Company, a Public Investment Fund company and Saudi Arabia’s commercial helicopter operator, to establish a "sandbox" for pre-commercial operations.Joby noted that the sandbox will serve as a base for evaluating potential air taxi operations in the region, with Joby conducting representative flights that include charging, airspace integration, and ground communications, similar to the flights it completed in the UAE earlier this year.Shares of Joby, which develops electric air taxis for commercial passenger service, were up nearly 2% in premarket trading.<h2 class="st-heading-2">Use Of FAA Certification</h2>The new partnership announced on Wednesday comes following Joby's announcement last week that it would collaborate with the General Authority of Civil Aviation (GACA) to support the development of the Kingdom's air taxi regulatory framework, using Federal Aviation Administration (FAA) certification standards as a foundation.According to a new memorandum of understanding with GACA, Joby will use FAA certification standards as a foundation to create a streamlined approval process for Joby’s aircraft in Saudi Arabia. Saudi Arabia joins the U.S., the U.K., Japan, South Korea and the UAE as another key launch market for Joby's air taxi service.<h2 class="st-heading-2">Joby’s Expansion In The Middle East</h2>In September, the company announced a long-term collaboration with the Ras Al Khaimah Transport Authority and Skyports Infrastructure to launch a passenger air taxi service network in the Emirate of Ras Al Khaimah by 2027.Joby had noted that as part of a six-year exclusive agreement, the company is also planning to start air taxi operations in Dubai in 2026. Joby, in November, said that the company signed a letter of intent to sell aircraft and services valued at up to $250 million to Alatau Advance Air Group dedicated to introducing air taxis to Kazakhstan.Retail sentiment on Joby remained unchanged in the ‘bearish’ territory, with message volumes at ‘low’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/JOBY">Shares of Joby</a> have gained nearly 125% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nokia-restructures-operations-into-network-and-mobile-infrastructure-segments-as-company-focuses-on-ai/cLPoIMyREBT">Nokia Restructures Operations Into Network And Mobile Infrastructure Segments As Company Focuses On AI</a>

ANA Holdings and Joby Aviation show a public demonstration flight of the Joby N5.42JX flying car at the World Expo 2025 Osaka on October 13, 2025 in Osaka, Japan.

Joby Aviation To Launch Electric Air Taxi Test Flights In Saudi Arabia

The company said that under the agreement, Joby will work together with Red Sea Global and The Helicopter Company to establish a "sandbox" for pre-commercial operations.

<ul class="summary-bullets"><li>The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to EMA on human medicines, which the agency uses to approve or reject a drug.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December.&nbsp;</li><li>If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.</li></ul>Shares of Anavex Life Sciences (AVXL) were in the spotlight on Monday as retail investors contemplated the possibilities of a positive take from a European Medicines Agency (EMA) committee for the company’s Alzheimer’s drug Blarcamesine.The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to the agency on human medicines, which the agency uses to approve or reject a drug. On Monday, CHMP <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-10-13-november-2025_en.pdf">included</a> Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13. The oral explanation for Blarcamesine is scheduled for Nov. 11, 2025, at 2:00 p.m.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>A Stocktwits user is keenly awaiting the statement from Anavex.<stembedurl>https://stocktwits.com/DipperDoo/message/635619033</stembedurl>Another user expressed hope that the committee would be convinced of the drug’s importance following the oral presentation.<stembedurl>https://stocktwits.com/Cresskill198/message/635618141</stembedurl>AVXL shares were down 9% at the time of writing. On Stocktwits, overall retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/57;" src="data:image/png;base64,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" width="587" height="57" alt="AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Anavex’s Application</h2>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Last month, Spirit of the Coast Analytics <a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-sparks-retail-banter-on-hopes-of-ema-conditional-nod-for-alzheimer-s-drug-big-pharma-tie-up/cLGP67oR3po">noted</a> that Blarcamesine’s existing Phase 2b/3 data, while limited in sample size and missing one co-primary endpoint, showed statistically strong results and sustained efficacy over 192 weeks in long-term studies. According to the analyst, the company is “likely” positioned for approval by the EMA in Q4 2025 or Q1 2026. &nbsp;AVXL stock is down by 38% this year and by about 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ifrx-stock-soars-pre-market-after-experimental-drug-shows-promise-in-treating-chronic-skin-diseases/cLPcS62RE2E">IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee

On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.

<ul class="summary-bullets"><li>The pharma major now expects adjusted earnings in the range of $3.00 to $3.15 for the full year.&nbsp;</li><li>Q3 revenue totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues.</li><li>Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand.&nbsp; &nbsp;</li></ul>Pfizer Inc. (PFE) on Tuesday raised its full-year adjusted earnings guidance to a range of $3.00 to $3.15, citing continued confidence in the business and progress with ongoing cost improvement initiatives.The company was previously expecting adjusted earnings in the range of $2.90 to $3.10 per share. Pfizer is now on track to deliver approximately $7.2 billion in overall anticipated net cost savings by the end of 2027, driven by cost improvement initiatives announced previously.The pharma major also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s206.q4cdn.com/795948973/files/doc_financials/2025/q3/Q3-2025-PFE-Earnings-Release-FINAL.pdf">reaffirmed</a> its full-year revenue guidance of $61.0 billion to $64.0 billion.<h2 class="st-heading-2">Q3 Earnings &nbsp;</h2>For the third quarter, the company reported adjusted earnings per share of $0.87, down from the $1.06 reported in the corresponding period of 2024, but above an analyst estimate of $0.64, according to data from Fiscal AI.Revenue for the three months through the end of September totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues, but above the estimated $16.5 billion.The company’s Paxlovid, an antiviral medication used to treat COVID-19, and its anti-COVID-19 vaccine Comirnaty, saw revenues in the quarter down by 55% and 19%, respectively, on a total basis.Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand. Other drugs to see revenue growth in the quarter include the heart disease drug Vyndaqel, which experienced a 10% increase to $ 1.59 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded 1% lower in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.PFE stock is down 7% this year and approximately 11% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-reportedly-drop-10-percent-in-october/cL28BCjR3CD">Tesla’s China-Made EV Sales Reportedly Drop 10% In October, Lowest Since May</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimates

The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027. 

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025

The company has increased its adjusted revenue outlook to a range of approximately $47.5 billion to $48.0 billion, up from a previous range of roughly $46.5 billion to $47.5 billion.

<ul class="summary-bullets"><li>The study was designed to study the efficacy and safety of Encaleret and enrolled 70 adults with ADH1.</li><li>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.</li><li>The company now plans to submit a new drug application to the U.S. Food and Drug Administration in the first half of 2026. &nbsp;</li></ul>Shares of BridgeBio Pharma, Inc. (BBIO) rose 4% on Wednesday afternoon after the company announced that its late-stage study of Encaleret in patients with autosomal dominant hypocalcemia type 1 met all primary and key secondary endpoints.This marks the company’s second positive trial result announcement this week. The Encaleret<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bridgebio.com/news/news-details/2025/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1/default.aspx"> study</a> was designed to study the efficacy and safety of the drug and enrolled 70 adults with ADH1– autosomal dominant hypocalcemia type 1 – a genetic disorder that causes low blood calcium levels, a condition known as hypocalcemia. Symptoms, which can range from none to severe, include muscle spasms, cramps, tingling sensations, and, in severe cases, seizures.<h2 class="st-heading-2">Trial Outcomes</h2>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment compared to 4% when on conventional therapy, the company said. Furthermore, the drug was well-tolerated, the company noted.The company now plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) in the first half of 2026, followed by an application to the European Medicines Agency.The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026. The trial in pediatric ADH1 is slated for the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BBIO">BBIO stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user termed the news great but expressed disappointment that the stock didn't rally further.<stembedurl>https://stocktwits.com/SugarSlim/message/634124724</stembedurl>Wednesday’s results come after the company <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">announced</a> on Monday that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.BBIO stock is up by 145% this year and by about 175% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results 

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026.

<ul class="summary-bullets"><li>Trian Fund Management said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.</li><li>The per-share price of $46 represents a 10.5% premium over the Oct. 24, 2025, closing price.</li><li>Trian said a mix of third-party equity and debt financing would fund the transaction consideration.</li></ul>Trian Fund Management, Nelson Peltz’s asset management firm, said that the company, along with General Catalyst Group Management, has submitted a non-binding proposal to buy the rest of Janus Henderson Group (JHG) that it does not own for $46.00 per share in cash.U.S.-listed shares of Janus Henderson jumped 18% in early trading on Monday. Trian said that, pursuant to the proposal, a newly formed entity on behalf of General Catalyst and Trian Fund would acquire all of the shares of Janus Henderson not currently owned by Trian.Trian said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.<h2 class="st-heading-2">Price Premium</h2>The per-share price of $46 represents a 10.5% premium over the Oct. 24, 2025, closing price. Trian said that the proposed transaction would derisk an investment that it believes is highly sensitive to capital market and geopolitical dynamics.Trian noted that the per-share price represents an over 56% premium to where the shares traded as recently as this past April, when capital market conditions were less favorable.“When Trian first disclosed its investment in the company in October 2020, the shares were trading at $21.60 per Share, and the company was consistently experiencing outflows in the mid-single digits,” Peltz said in an email to the board of Janus Henderson.“Since that time, the company’s board of directors and management team (led by CEO Ali Dibadj) have achieved a highly successful operational turnaround of the company’s business, which today consistently generates positive net inflows while enjoying mid-30% operating margins,” he added.<h2 class="st-heading-2">Financing Details Of The Proposed Transaction</h2>The transaction consideration would be funded by a mix of equity and debt financing from third parties, including limited partners of Trian and General Catalyst, as well as their affiliated funds, Trian said.“It is our expectation that the board will appoint a special committee of independent, disinterested directors (the “Special Committee”) to consider the proposed transaction and make a recommendation to the Board,” Peltz said.Retail sentiment on Janus Henderson remained unchanged in the ‘bullish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/JHG">Shares of Janus Henderson</a> have gained nearly 16% this year and have jumped over 21% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/organon-ceo-kevin-ali-resigns-audit-probe-into-wholesaler-sales-practices/cLG0eYHR3M8">Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices</a>

Nelson Peltz and Elon Musk attend the Premiere of "Lola" at Regency Bruin Theatre on February 03, 2024 in Los Angeles, California.

JHG Stock Rockets 15% Pre-Market After Receiving A Non-Binding Proposal For $46 Per Share

Trian Fund Management said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.

EAOR
iShares ESG Aware 60/40 Balanced Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest EAOR News

EAORiShares ESG Aware 60/40 Balanced Allocation ETF